Anti-CD19/CD3 Bispecific Antibody GNR-084

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody GNR-084 binds to both the CD3 antigen on T-cells and the CD19 antigen expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.

**Synonyms:** - Anti-CD19/Anti-CD3 Bispecific Antibody GNR-084 - Anti-CD19/CD3 Bispecific T-cell Engager Antibody GNR-084 - CD19 x CD3 Bispecific Antibody GNR-084 - GNR 084 - GNR-084 - GNR084